^
Association details:
| Biomarker: | CD44 positive |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | Sutent (sunitinib) (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
CD44 Is Involved in Sunitinib Resistance and Poor Progression-free Survival After Sunitinib Treatment of Renal Cell Carcinoma
Excerpt:
This study aimed to examine the role of CD44 in sunitinib resistance and as a predictive marker in mRCC….CD44 expression in mRCC patients treated with first-line sunitinib was determined by immunohistochemistry. We validated the findings of this study by in silico analysis....CD44-positive cases were associated with poor progression-free survival (PFS) after first-line sunitinib treatment.
DOI:
10.21873/anticanres.15301
